Alnylam Pharmaceuticals– tag –
-
2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era
MiraScope Unknown Overview The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceut... -
siRNA Overcomes Gene Silencing Challenges with LNP and GalNAc Conjugation, Expanding Therapeutic Applications
Inside Therapeutics USA Overview Inside Therapeutics details how siRNA, while offering transformative gene silencing, is overcoming delivery challenges through lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc) conjugation tech... -
RNA Medicines Enter ‘Second Act’ Post-COVID-19, Focusing on Extrahepatic Delivery Beyond the Liver
European Biotechnology Magazine Germany Overview RNA therapeutics are entering a 'second act' after the success of mRNA vaccines during the COVID-19 pandemic, with a critical focus on developing effective delivery technologies to extrahe... -
Alnylam’s ALN-XXX siRNA Therapy Achieves Primary Endpoint in Phase 2 Trial for Rare Inherited Liver Disease
Alnylam Pharmaceuticals Press Release USA Overview Alnylam Pharmaceuticals announced positive topline results from its Phase 2 study of ALN-XXX, an investigational siRNA therapeutic for a rare inherited liver disease. The trial successfu...
1